Navigation Links
Cholesterol-lowering drugs may also lower PSA, but whether they cut cancer risk is still not known
Date:10/28/2008

DURHAM, N.C. -- Popular cholesterol-busting drugs -- statins -- appear to lower men's PSA values along with their cholesterol levels, according to researchers in the Duke Prostate Center and the Durham Veterans Affairs Medical Center. But whether the drugs prevent prostate cancer growth or just mask it is not known yet.

"Previous studies had shown that men taking statins were less likely to develop advanced forms of prostate cancer but no one had looked at the relationship between the drugs and prostate-specific antigen, or PSA, a biomarker that is correlated with cancer growth and is the most common prostate cancer screening tool," said Stephen Freedland, M.D., a urologist at Duke and senior investigator on the study. "Our study represents a move to understand if and how statins influence prostate biology and whether they are really reducing cancer risk, or simply making PSA a less effective screening tool."

The study was published in the October 28, 2008 issue Journal of the National Cancer Institute. The research was funded by the United States Department of Veterans Affairs, The United States Department of Defense and the American Urological Association Foundation's Astellas Rising Star in Urology Award, given to Freedland.

The researchers reviewed the medical records of 1214 men who were prescribed statins between 1990 and 2006 at the Durham Veterans Affairs Medical Center. Men with prostate cancer were excluded from the study.

They found that PSA levels declined by an average of about four percent after starting statins, compared to no decline in the year before starting the statins, Freedland said. Bigger declines occurred in men who took higher doses of statins and who had the largest decreases in cholesterol levels. Also, the higher the PSA levels were initially, the more they were seen to decline, Freedland said.

"This is important because we had some men who started with PSA levels that looked to be headed in the direction of a recommended biopsy to look for prostate cancer, but they weren't there quite yet," said Robert Hamilton, M.D., a urologist at the University of Toronto, who served as this study's lead investigator while he was a research fellow at Duke. "In a good proportion of these men, the PSA levels declined sufficiently to a point where physicians might not recommend a biopsy, so it's really important that we understand what's at work here, so we can be sure we're not missing cancers because of deceptively low PSA levels."

"Our next step will be to further investigate the interplay between statins and prostate biology to determine whether their effect on PSA corresponds to, or is independent of, cancer growth," Freedland said. "Depending on the outcomes, this could have big public health implications, whether we need to change the way we screen men who are taking statins or we are able to harness the mechanism by which statins work to reduce risk or even treat cancer."

Statins were the most commonly prescribed class of drugs in the United States in 2007 and they work by blocking the production of a critical enzyme the body needs to make cholesterol. There are several types of cholesterol found in the blood; when the level of so-called "bad" cholesterol, or low density lipoprotein (LDL) is too high and concentrations of "good" cholesterol, or high density lipoprotein (HDL) too low, it can lead to cardiovascular disease.


'/>"/>

Contact: Lauren Shaftel Williams
lauren.shaftel@duke.edu
919-684-4966
Duke University Medical Center
Source:Eurekalert

Related medicine news :

1. Discoverers of Small Regulatory RNAs and Cholesterol-Lowering Drugs to Receive Lasker Awards for Medical Research
2. Study shows cholesterol-lowering power of dietitian visits
3. Cholesterol-Lowering Statins Tied to Tendon Woes
4. Cholesterol-Lowering Drugs May Ease Irregular Heartbeat
5. New Type of Cholesterol-Lowering Drug Shows Promise
6. Many Patients Stop Taking Cholesterol-Lowering Drugs
7. Cholesterol-lowering drug linked to sleep disruptions
8. Topical treatment for cold sores achieves efficacy of oral drugs; represents paradigm shift
9. Common Heart Drugs May Hamper Blood Thinner
10. The Market for Disease-Modifying Osteoarthritis Drugs Will Experience Exponential Growth, Increasing From $477 Million in 2007 to Nearly $3.8 Billion in 2017
11. Albertsons LLC Launches $4.99 Prescription Discount Program Covering Over 500 Generic Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... ... Business Brilliance Awards under the Best New Product Launch category. Gensuite’s entry on ... user experience. , BOC Global Events & Training Group is a professional event ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... “Walking With ... of stories that will inspire the reader to be aware of God's direction in ... of published author, Sanford Smith, retired teacher and active church leader. , ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... NuevaCare, a ... Peninsula region, is proud to announce new city-specific pages as part of its ambitious ... the elderly, they often look, first, for local agencies serving their city. The new ...
(Date:12/6/2016)... ... December 06, 2016 , ... Individuals who seek to reduce ... drinking more water or limiting their exposure to the sun, according to a November ... group Beverly Hills Physicians (BHP) notes that, while preventive measures to help keep ourselves ...
(Date:12/6/2016)... ... 06, 2016 , ... Mount Sinai Health System today announced the creation of ... can confer and order 3D models for their cases. Virtual reality, simulation, and ... times. This resource will be the first of its kind catering to the ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... 2016 United Kingdom Ophthalmic Diagnostic Equipment ... new report, "United Kingdom Ophthalmic Diagnostic Equipment Market ... the United Kingdom Ophthalmic Diagnostic Equipment market. The ... volume (in units) and average prices (USD) within ... Ultrasound Imaging Systems, Corneal Topography Systems, Ophthalmoscopes, Perimeters, ...
(Date:12/5/2016)... -- Spain Glaucoma Surgery Devices Market Outlook to 2022 ... Devices Market Outlook to 2022", provides key market data ... provides value, in millions of US dollars, volume (in ... Canaloplasty Micro Catheters and Glaucoma Drainage Devices. The ... for each of these market segements, and global corporate-level ...
(Date:12/5/2016)... -- Sangamo BioSciences, Inc. (Nasdaq: SGMO ), the ... and manufacturing data that support SB-525, its gene therapy program ... of the American Society of Hematology (ASH) being held in ... 2016. "We have developed an improved gene therapy ... highly competitive, and we remain on track to file an ...
Breaking Medicine Technology: